Major Adverse Cardiovascular Events (MACE) | Norton Healthcare

Indication: Major Adverse Cardiovascular Events (MACE)

SELECT – Semaglutide effects on cardiovascular outcomes in people with overweight or obesity

Sub-indication: Major Adverse Cardiovascular Events (MACE)

Study Type: Drug Study

Principal Investigator: Joseph Lash, M.D.
Norton Heart & Vascular Institute

Sponsor: Sponsor: Novo Nordisk, Inc.

Learn more at ClinicalTrials.gov

Email for more information: NCRG@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.